Oxford Sciences Innovation has returned to back a $30m funding round for Genomics, having previously contributed to a 2018 series B round.
Genomics, a UK-based precision healthcare spinout of University of Oxford, closed a $30m funding round yesterday backed by university venture fund Oxford Sciences Innovation (OSI).
Foresite Capital and F-Prime Capital, an investment affiliate of financial services group Fidelity, and Lansdowne Partners also participated in the round.
Founded in 2014, Genomics has developed a machine learning-powered genomic analytics platform that determines the risk of individuals for common diseases before they manifest.
Apart from delivering its population health management services and clinical decision support tools, the company also uses its insights to support the discovery and development of treatments. It will use the equity financing to expand its platform.
Prof Sir Peter Donnelly, co-founder and CEO of Genomics, said: “This new approach to healthcare, called Genomic Prevention, can identify people at risk for developing each disease early, and is critical to driving more efficient screening and a prevention first approach to healthcare.
“More successful disease prevention will improve patient lives and make healthcare systems more sustainable.”
Genomics raised $42m in a series B round in 2018 backed by OSI, commercialisation firm IP Group, drug manufacturer Vertex Pharmaceuticals, F-Prime Capital and Foresite Capital.
Landsdowne Partners, Invesco Perpetual and Tanarra also contributed to the series B round, as did the now-defunct Woodford Investment Management.
University of Oxford contributed to a $16.2m series A round in 2014 together with IP Group and its IP Venture Fund II, Invesco Perpetual, Lansdowne, Woodford and Wylie Family Trust.